Re: activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

Eur Urol. 2015 Feb;67(2):348-9. doi: 10.1016/j.eururo.2014.11.019.

Author

Anders Bjartell¹

Affiliation

¹ Department of Urology, Skåne University Hospital Malmö, Malmö, Sweden; Department of Clinical Sciences Malmö, Division of Urological Cancers, Lund University, Lund, Sweden. Electronic address: [email protected].

PMID: 25760250
DOI: 10.1016/j.eururo.2014.11.019

No abstract available

Publication types

Comment

MeSH terms

Androgen Receptor Antagonists / pharmacology*
Humans
Male
Prostate-Specific Antigen / blood*
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / mortality*

Substances

Androgen Receptor Antagonists
Prostate-Specific Antigen